Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer
Article first published online: 29 JAN 2010
Copyright © 2010 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 101, Issue 5, pages 396–400, 1 April 2010
How to Cite
Huh, J. W., Oh, B. R., Kim, H. R. and Kim, Y. J. (2010), Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J. Surg. Oncol., 101: 396–400. doi: 10.1002/jso.21495
- Issue published online: 26 MAR 2010
- Article first published online: 29 JAN 2010
- Manuscript Accepted: 30 NOV 2009
- Manuscript Received: 7 OCT 2009
- Chonnam National University Research Institute of Medical Sciences
- carcinoembryonic antigen;
- colon cancer
We evaluated the prognostic value of the preoperative serum carcinoembryonic antigen (CEA) level in patients with colon cancer.
We reviewed 474 patients who underwent potentially curative resection for nonmetastatic colon cancer. Patients were categorized into two groups according to the preoperative serum CEA level: low CEA (<5 ng/ml) and high CEA (≥5 ng/ml) groups.
During the median 45-month follow-up period, the 5-year overall and disease-free survival rates for patients with a low CEA level were 81.7% and 82.4%, respectively, which were significantly higher than the rates for those with a high CEA level (69.9%; P = 0.011 and 70.6%; P = 0.002, respectively). A multivariate analysis revealed that a preoperative serum CEA level was a significant independent prognostic factor for both overall survival (P = 0.021) and disease-free survival (P = 0.026). Both the overall and disease-free survival rates in patients with stage II tumors differed significantly between the low and high CEA groups, whereas the rates did not different between those with stage I and III tumors.
Preoperative serum CEA is a reliable predictor of recurrence and survival after curative surgery in patients with colon cancer, particularly in those classified as having stage II disease. J. Surg. Oncol. 2010; 101:396–400. © 2010 Wiley-Liss, Inc.